HARVARD BIOSCIENCE, INC. Financials Harvard Bioscience, Inc.
Equities
HBIO
US4169061052
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.25 USD | -0.61% |
|
-4.37% | -38.69% |
| May. 07 | Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 116.1 | 167.2 | 287.7 | 115.4 | 228.4 | 142 | - | - |
| Enterprise Value (EV) 1 | 116.1 | 167.2 | 287.7 | 115.4 | 228.4 | 142 | 142 | 142 |
| P/E ratio | -25.4 x | -21.5 x | -705 x | -12 x | -66.9 x | -40.9 x | 43.6 x | 21.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1 x | 1.64 x | 2.42 x | 1.02 x | 2.03 x | 1.27 x | 1.14 x | 1.03 x |
| EV / Revenue | 1 x | 1.64 x | 2.42 x | 1.02 x | 2.03 x | 1.27 x | 1.14 x | 1.03 x |
| EV / EBITDA | - | 10.7 x | 15.6 x | 10.6 x | 15.7 x | 8.35 x | 6.4 x | - |
| EV / FCF | 17 x | 20.4 x | 4,294 x | -263 x | 18.7 x | 28.4 x | 15.3 x | 11.3 x |
| FCF Yield | 5.88% | 4.89% | 0.02% | -0.38% | 5.36% | 3.52% | 6.55% | 8.87% |
| Price to Book | 1.43 x | 2.23 x | 3.65 x | 1.64 x | 3.18 x | 2.01 x | 1.88 x | 1.64 x |
| Nbr of stocks (in thousands) | 38,066 | 38,976 | 40,811 | 41,658 | 42,688 | 43,430 | - | - |
| Reference price 2 | 3.050 | 4.290 | 7.050 | 2.770 | 5.350 | 3.270 | 3.270 | 3.270 |
| Announcement Date | 2/26/20 | 3/10/21 | 3/8/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 116.2 | 102.1 | 118.9 | 113.3 | 112.2 | 112 | 124 | 138 |
| EBITDA 1 | - | 15.67 | 18.5 | 10.84 | 14.55 | 17 | 22.2 | - |
| EBIT 1 | 14.85 | 13.95 | 16.72 | 9.497 | 13.11 | 12.3 | 18.2 | 22.9 |
| Operating Margin | 12.78% | 13.67% | 14.06% | 8.38% | 11.68% | 10.99% | 14.67% | 16.59% |
| Earnings before Tax (EBT) 1 | -5.502 | -7.292 | -0.14 | -9.179 | -2.556 | -2.85 | 4.55 | 9.4 |
| Net income 1 | -4.687 | -7.81 | -0.288 | -9.516 | -3.415 | -3.6 | 3.3 | 7.1 |
| Net margin | -4.03% | -7.65% | -0.24% | -8.4% | -3.04% | -3.22% | 2.66% | 5.14% |
| EPS 2 | -0.1200 | -0.2000 | -0.0100 | -0.2300 | -0.0800 | -0.0800 | 0.0750 | 0.1500 |
| Free Cash Flow 1 | 6.829 | 8.179 | 0.067 | -0.438 | 12.24 | 5 | 9.3 | 12.6 |
| FCF margin | 5.88% | 8.01% | 0.06% | -0.39% | 10.9% | 4.47% | 7.5% | 9.13% |
| FCF Conversion (EBITDA) | - | 52.21% | 0.36% | - | 84.12% | 29.41% | 41.89% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 281.82% | 177.46% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 3/10/21 | 3/8/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 33.06 | 28.78 | 29.21 | 26.92 | 28.43 | 29.98 | 28.76 | 25.36 | 28.15 | 24.51 | 26.4 | 28.9 | 32.15 | 27.6 | 32.1 |
| EBITDA 1 | 5.748 | 2.748 | 3.433 | 1.066 | 3.683 | 4.755 | 3.9 | 2.246 | 3.65 | 1.614 | 4.5 | 4.7 | 6.2 | 2.8 | 6.9 |
| EBIT 1 | 5.278 | 2.366 | 3.057 | 0.702 | 3.369 | 4.434 | 3.572 | 1.841 | 3.265 | 1.171 | 2.5 | 3.6 | 5 | - | - |
| Operating Margin | 15.97% | 8.22% | 10.47% | 2.61% | 11.85% | 14.79% | 12.42% | 7.26% | 11.6% | 4.78% | 9.47% | 12.46% | 15.55% | - | - |
| Earnings before Tax (EBT) 1 | 1.131 | -7.018 | 3.421 | -4.69 | -0.892 | 1.207 | -2.098 | -0.562 | -1.103 | -4.484 | -0.6 | 0.3 | 1.95 | -1.3 | 2.4 |
| Net income 1 | 0.961 | -6.88 | 2.435 | -3.405 | -1.666 | 0.622 | -0.98 | -1.239 | -1.818 | -4.694 | -0.6 | 0.2 | 1.45 | -1.3 | 1.8 |
| Net margin | 2.91% | -23.91% | 8.34% | -12.65% | -5.86% | 2.08% | -3.41% | -4.89% | -6.46% | -19.15% | -2.27% | 0.69% | 4.51% | -4.71% | 5.61% |
| EPS 2 | 0.0200 | -0.1700 | 0.0600 | -0.0800 | -0.0400 | 0.0100 | -0.0200 | -0.0300 | -0.0400 | -0.1100 | -0.0150 | 0.005000 | 0.0350 | -0.0300 | 0.0400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/8/22 | 5/4/22 | 8/4/22 | 11/8/22 | 3/9/23 | 4/25/23 | 8/8/23 | 11/7/23 | 3/7/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 6.83 | 8.18 | 0.07 | -0.44 | 12.2 | 5 | 9.3 | 12.6 |
| ROE (net income / shareholders' equity) | -5.72% | -9.86% | -0.36% | -12.2% | -4.7% | -6.3% | 3.8% | 7.6% |
| ROA (Net income/ Total Assets) | -2.82% | -4.86% | -0.18% | -6.19% | -2.42% | -3.5% | 2.2% | 4.7% |
| Assets 1 | 166.5 | 160.6 | 159.1 | 153.9 | 141.4 | 102.9 | 150 | 151.1 |
| Book Value Per Share 2 | 2.140 | 1.930 | 1.930 | 1.690 | 1.680 | 1.630 | 1.740 | 1.990 |
| Cash Flow per Share 2 | 0.2100 | 0.2400 | 0.1800 | -0.0500 | 0.3300 | 0.0600 | 0.2400 | 0.3200 |
| Capex 1 | 1.22 | 1.15 | 1.2 | 1.59 | 1.79 | 3.4 | 4 | 4 |
| Capex / Sales | 1.05% | 1.13% | 1.01% | 1.4% | 1.59% | 3.04% | 3.22% | 2.9% |
| Announcement Date | 2/26/20 | 3/10/21 | 3/8/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.27
USD
Average target price
7
USD
Spread / Average Target
+114.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.88% | 142M | |
| +11.91% | 227B | |
| +15.46% | 198B | |
| +18.58% | 142B | |
| +30.36% | 111B | |
| +0.65% | 64.16B | |
| +17.74% | 54.1B | |
| +5.82% | 51.41B | |
| +11.23% | 45.32B | |
| +5.73% | 37.32B |
- Stock Market
- Equities
- HBIO Stock
- Financials Harvard Bioscience, Inc.
